Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4918498 | 0.90 | MEN1 (0.37) | MEN1MAPTKMT2ACHRNB2CHRNA4 | |
| SCHEMBL4920982 | 0.88 | MAPT (0.38) | MEN1MAPTKMT2ACHRNB2CHRNA4 | |
| SCHEMBL4158307 | 0.88 | MAPT (0.39) | MEN1MAPTKMT2ACHRNB2CHRNA4 | |
| Bromide SCHEMBL4920808 | 0.82 | HPGD (0.39) | MEN1MAPTKMT2ANPC1RAB9A | |
| Bromide SCHEMBL2810282 | 0.82 | NPC1 (0.39) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL2813865 | 0.80 | NPC1 (0.41) | MEN1MAPTKMT2ANPC1RAB9A | |
| Bromide SCHEMBL2813445 | 0.79 | HPGD (0.36) | MEN1MAPTKMT2ANPC1RAB9A | |
| Bromide SCHEMBL2813414 | 0.78 | MEN1 (0.41) | MEN1MAPTKMT2ACHRNB2CHRNA4 | |
| SCHEMBL2813548 | 0.77 | HPGD (0.36) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL2816371 | 0.76 | MEN1 (0.41) | MEN1MAPTKMT2ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | MEN1 535/4885MAPT 695/4885KMT2A 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.